Patient Name Mr. DEVI SAHAY MEENA Lab No 4025200 UHID 40010868 **Collection Date** 26/02/2024 9:25AM 26/02/2024 9:35AM Age/Gender 52 Yrs/Male **Receiving Date Report Date IP/OP Location** O-OPD 26/02/2024 6:10PM

Referred By Dr. EHS CONSULTANT Report Status Final

Mobile No. 8290091444

BIOCHEMISTRY

 Test Name
 Result
 Unit
 Biological Ref. Range

 BLOOD GLUCOSE (FASTING)
 Sample: Fl. Plasma

 BLOOD GLUCOSE (FASTING)
 93.0
 mg/dl
 71 - 109

Method: Hexokinase assay.

Interpretation: -Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

BLOOD GLUCOSE (PP) Sample: PLASMA

BLOOD GLUCOSE (PP) 134 mg/dl Non – Diabetic: - < 140 mg/dl Pre – Diabetic: - 140-199 mg/dl

Diabetic: - >=200 mg/dl

Method: Hexokinase assay.

THYROID T3 T4 TSH Sample: Serum

Т3	1.520	ng/mL	0.970 - 1.690
T4	9.33	ug/dl	5.53 - 11.00
TSH	1.78	μIU/mL	0.40 - 4.05

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

Patient Name	Mr. DEVI SAHAY MEENA	Lab No	4025200
UHID	40010868	Collection Date	26/02/2024 9:25AM
Age/Gender IP/OP Location	52 Yrs/Male	Receiving Date	26/02/2024 9:35AM
	O-OPD	Report Date	26/02/2024 6:10PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	8290091444		

BIOCHEMISTRY

T3:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T3 is utilized in thediagnosis of T3-hyperthyroidism the detection of early stages ofhyperthyroidism and for indicating a diagnosis of thyrotoxicosis factitia.

T4:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs acompetitive test principle with an antibody specifically directed against T4.

TSH - THYROID STIMULATING HORMONE :- ElectroChemiLuminescenceImmunoAssay - ECLIA

88

1.6

41

Interpretation: - The determination of TSH serves as theinitial test in thyroid diagnostics. Even very slight changes in the concentrations of the free thyroid hormones bring about much greater opposite changes in the TSH levels.

LFT (LIVER FUNCTION TEST)				Sample: Serum
BILIRUBIN TOTAL	0.32	mg/dl	0.00 - 1.20	
BILIRUBIN INDIRECT	0.17 L	mg/dl	0.20 - 1.00	
BILIRUBIN DIRECT	0.15	mg/dl	0.00 - 0.30	
SGOT	21.0	U/L	0.0 - 40.0	
SGPT	20.1	U/L	0.0 - 41.0	
TOTAL PROTEIN	7.13	g/dl	6.6 - 8.7	
ALBUMIN	4.36	g/dl	3.5 - 5.2	
GLOBULIN	2.8		1.8 - 3.6	

U/L

Ratio

U/L

40 - 129

1.5 - 2.5

10.0 - 60.0

RESULT ENTERED BY: SUNIL EHS

ALKALINE PHOSPHATASE

A/G RATIO

GGTP

Dr. ABHINAY VERMA

Patient Name Mr. DEVI SAHAY MEENA Lab No 4025200 UHID **Collection Date** 26/02/2024 9:25AM 40010868 26/02/2024 9:35AM Age/Gender **Receiving Date** 52 Yrs/Male Report Date O-OPD **IP/OP Location** 26/02/2024 6:10PM

Referred By Dr. EHS CONSULTANT Report Status Final

Mobile No. 8290091444

BIOCHEMISTRY

BILIRUBIN TOTAL :- Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structive.

BILIRUBIN DIRECT :- Method: Diazo method Interpretation:-Determinations of direct bilirubin measure mainly conjugated, water soluble bilirubin.

SGOT - AST :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGOT(AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

SGPT - ALT :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT(ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

TOTAL PROTEINS: - Method: Bivret colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder.

ALBUMIN: - Method: Colorimetric (BCP) assay. Interpretation:-For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis, nutritional status.

ALKALINE PHOSPHATASE: - Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. GGTP-GAMMA GLUTAMYL TRANSPEPTIDASE: - Method: Enzymetic colorimetric assay. Interpretation:-y-glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

LIPID PROFILE

TOTAL CHOLESTEROL	151		<200 mg/dl :- Desirable 200-240 mg/dl :- Borderline >240 mg/dl :- High
HDL CHOLESTEROL	40.9		High Risk :-<40 mg/dl (Male), <40 mg/dl (Female) Low Risk :->=60 mg/dl (Male), >=60 mg/dl (Female)
LDL CHOLESTEROL	97.4		Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl
CHOLESTERO VLDL	23	mg/dl	10 - 50
TRIGLYCERIDES	114		Normal :- <150 mg/dl Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl
CHOLESTEROL/HDL RATIO	4.0	%	

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

Patient Name Mr. DEVI SAHAY MEENA Lab No 4025200 UHID 40010868 **Collection Date** 26/02/2024 9:25AM 26/02/2024 9:35AM **Receiving Date** Age/Gender 52 Yrs/Male **Report Date IP/OP Location** O-OPD 26/02/2024 6:10PM

Referred By Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 8290091444

BIOCHEMISTRY

CHOLESTEROL TOTAL :- Method: CHOD-PAP enzymatic colorimetric assay.

interpretation:-The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders. HDL CHOLESTEROL :- Method:-Homogenous enzymetic colorimetric method.

Interpretation: -HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease. LDL CHOLESTEROL :- Method: Homogenous enzymatic colorimetric assay.

Interpretation:-LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived form VLDL rich in TG by the action of various lipolytic enzymes and are synthesized in the liver.
CHOLESTEROL VLDL: - Method: VLDL Calculative

Interpretation: -High triglycerde levels also occur in various diseases of liver, kidneys and pancreas.

DM, nephrosis, liver obstruction.

CHOLESTEROL/HDL RATIO :- Method: Cholesterol/HDL Ratio Calculative

Sample: Serum

UREA	17.4	mg/dl	16.60 - 48.50
BUN	8.0	mg/dl	6 - 20
CREATININE	0.80	mg/dl	0.70 - 1.20
SODIUM	132.0 L	mmol/L	136 - 145
POTASSIUM	4.44	mmol/L	3.50 - 5.50
CHLORIDE	95.8 L	mmol/L	98 - 107
URIC ACID	5.5	mg/dl	3.4 - 7.0
CALCIUM	8.99	mg/dl	8.60 - 10.00

RESULT ENTERED BY: SUNIL EHS

Dr. ABHINAY VERMA

Patient Name Mr. DEVI SAHAY MEENA Lab No 4025200 UHID **Collection Date** 26/02/2024 9:25AM 40010868 26/02/2024 9:35AM Age/Gender **Receiving Date** 52 Yrs/Male Report Date O-OPD **IP/OP Location** 26/02/2024 6:10PM

Referred By Dr. EHS CONSULTANT Report Status Final

Mobile No. 8290091444

BIOCHEMISTRY

CREATININE - SERUM :- Method: -Jaffe method, Interpretation:-To differentiate acute and chronic kidneydisease.
URIC ACID :- Method: Enzymatic colorimetric assay. Interpretation:- Elevated blood concentrations of uricacid are renal diseases with decreased excretion of waste products, starvation, drug abuse and increased alcohol consume.

SODIUM:- Method: ISE electrode. Interpretation:-Decrease: Prolonged vomiting or diarrhea, diminished reabsorption in the kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake and kidney reabsorption.

POTASSIUM:- Method: ISE electrode. Intrpretation:-Low level: Intake excessive loss formbodydue to diarrhea, vomiting

renal failure, High level: Dehydration, shock severe burns, DKA, renalfailure.

CHLORIDE - SERUM: - Method: ISE electrode. Interpretation: -Decrease: reduced dietary intake, prolonged vomiting and reduced renal reabsorption as well as forms of acidosisand alkalosis.

Increase: dehydration, kidney failure, some form ofacidosis, high dietary or parenteral chloride intake, and salicylate poisoning.

UREA:- Method: Urease/GLDH kinetic assay. Interpretation:-Elevations in blood urea nitrogenconcentration are seen in inadequate renal perfusion, shock, diminished bloodvolume, chronic nephritis, nephrosclerosis, tubular necrosis, glomerularnephritis and UTI.

CALCIUM TOTAL: - Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usually associated with hypercalcemia. Increased serum calcium levels may also be observed in multiple myeloma and other neoplastic diseases. Hypocalcemia may

beobserved in hypoparathyroidism, nephrosis, and pancreatitis.

Sample: WHOLE BLOOD EDTA

HBA1C 5.8 % < 5.7% Nondiabetic

5.7-6.4% Pre-diabetic > 6.4% Indicate Diabetes

Known Diabetic Patients
< 7 % Excellent Control
7 - 8 % Good Control
> 8 % Poor Control

 ${\tt Method: - Turbidimetric\ inhibition\ immunoassay\ (TINIA)}$

Interpretation:-Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient. The approximate relationship between HbA1C and mean blood glucose values during the preceding 2 to 3 months.

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Page: 5 Of 10

Patient Name Mr. DEVI SAHAY MEENA Lab No 4025200 UHID 40010868 **Collection Date** 26/02/2024 9:25AM 26/02/2024 9:35AM Age/Gender **Receiving Date** 52 Yrs/Male **Report Date IP/OP Location** O-OPD 26/02/2024 6:10PM

Referred By Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 8290091444

BLOOD BANK INVESTIGATION

Biological Ref. Range Test Name Result Unit

BLOOD GROUPING "B" Rh Positive

1. Both forward and reverse grouping performed.
2. Test conducted on EDTA whole blood.

RESULT ENTERED BY: SUNIL EHS

Dr. ABHINAY VERMA

Patient Name Mr. DEVI SAHAY MEENA Lab No 4025200 **Collection Date** 26/02/2024 9:25AM UHID 40010868 26/02/2024 9:35AM Age/Gender **Receiving Date** 52 Yrs/Male **Report Date** O-OPD **IP/OP Location** 26/02/2024 6:10PM Dr. EHS CONSULTANT **Referred By Report Status** Final

Mobile No. 8290091444

CLINICAL PATHOLOGY

Test Name	Result	Unit	Biological Ref. Range	
URINE SUGAR (POST PRANDIAL)				Sample: Urine
URINE SUGAR (POST PRANDIAL)	NEGATIVE		NEGATIVE	
URINE SUGAR (RANDOM)				Sample: Urine
URINE SUGAR (RANDOM)	NEGATIVE		NEGATIVE	
				Sample: Urine
PHYSICAL EXAMINATION				
VOLUME	25	ml		
COLOUR	PALE YELLOW		P YELLOW	
APPEARANCE	CLEAR		CLEAR	
CHEMICAL EXAMINATION				
PH	6.0		5.5 - 7.0	
SPECIFIC GRAVITY	1.000		1.016-1.022	
PROTEIN	NEGATIVE		NEGATIVE	
SUGAR	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE		NEGATIVE	
BLOOD	NEGATIVE			
KETONES	NEGATIVE		NEGATIVE	
NITRITE	NEGATIVE		NEGATIVE	
UROBILINOGEN	NEGATIVE		NEGATIVE	
LEUCOCYTE	NEGATIVE		NEGATIVE	
MICROSCOPIC EXAMINATION				
WBCS/HPF	1-2	/hpf	0 - 3	
RBCS/HPF	0-0	/hpf	0 - 2	
EPITHELIAL CELLS/HPF	1-2	/hpf	0 - 1	
CASTS	NIL		NIL	
CRYSTALS	NIL		NIL	

RESULT ENTERED BY: SUNIL EHS

Dr. ABHINAY VERMA

Mr. DEVI SAHAY MEENA **Patient Name** Lab No 4025200 UHID 40010868 **Collection Date** 26/02/2024 9:25AM 26/02/2024 9:35AM Age/Gender 52 Yrs/Male **Receiving Date Report Date IP/OP Location** O-OPD 26/02/2024 6:10PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

8290091444 Mobile No.

CLINICAL PATHOLOGY

NIL **BACTERIA** NIL **OHTERS** NIL NIL

Methodology:-

Methodology:Glucose: GOD-POD, Bilirubin: Diazo-Azo-coupling reaction with a diazonium, Ketone: Nitro Pruside reaction, Specific
Gravity: Proton re;ease from ions, Blood: Psuedo-Peroxidase activity oh Haem moiety, pH: Methye Red-Bromothymol Blue
(Double indicator system), Protein: H+ Release by buffer, microscopic & chemical method.
interpretation: Diagnosis of Kidney function, UTI, Presence of Protein, Glucoses, Blood. Vocubulary syntax: Kit insert

RESULT ENTERED BY: SUNIL EHS

Dr. ABHINAY VERMA

Patient Name Mr. DEVI SAHAY MEENA Lab No 4025200 UHID 40010868 **Collection Date** 26/02/2024 9:25AM 26/02/2024 9:35AM Age/Gender **Receiving Date** 52 Yrs/Male Report Date 26/02/2024 6:10PM **IP/OP Location** O-OPD **Referred By** Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 8290091444

HEMATOLOGY

Test Name	Result	Unit	Biological Ref. Ra	nge
CBC (COMPLETE BLOOD COUNT)				Sample: WHOLE BLOOD EDTA
HAEMOGLOBIN	14.1	g/dl	13.0 - 17.0	
PACKED CELL VOLUME(PCV)	41.9	%	40.0 - 50.0	
MCV	92.3 H	fl	82 - 92	
MCH	31.1	pg	27 - 32	
MCHC	33.7	g/dl	32 - 36	
RBC COUNT	4.54	millions/cu.mm	4.50 - 5.50	
TLC (TOTAL WBC COUNT)	9.10	10^3/ uL	4 - 10	
DIFFERENTIAL LEUCOCYTE COUNT				
NEUTROPHILS	57.4	%	40 - 80	
LYMPHOCYTE	29.6	%	20 - 40	
EOSINOPHILS	3.0	%	1 - 6	
MONOCYTES	9.5	%	2 - 10	
BASOPHIL	0.5 L	%	1 - 2	
PLATELET COUNT	3.21	lakh/cumm	1.500 - 4.500	

HAEMOGLOBIN :- Method:-SLS HemoglobinMethodology by Cell Counter.Interpretation:-Low-Anemia, High-Polycythemia.

MCV :- Method:- Calculation bysysmex.
MCH :- Method:- Calculation bysysmex.
MCHC :- Method:- Calculation bysysmex.

RBC COUNT :- Method:-Hydrodynamicfocusing.Interpretation:-Low-Anemia, High-Polycythemia.

TLC (TOTAL WBC COUNT) :- Method: -Optical Detectorblock based on Flowcytometry. Interpretation: -High-Leucocytosis, Low-Leucopenia.

NEUTROPHILS :- Method: Optical detectorblock based on Flowcytometry LYMPHOCYTS : - Method: Optical detectorblock based on FlowcytometryEOSINOPHILS :- Method: Optical detectorblock based on Flowcytometry MONOCYTES :- Method: Optical detectorblock based on Flowcytometry BASOPHIL :- Method: Optical detectorblock based on Flowcytometry

PLATELET COUNT :- Method:-Hydrodynamicfocusing method.Interpretation:-Low-Thrombocytopenia, High-Thrombocytosis.

HCT: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia. NOTE: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

ESR (ERYTHROCYTE SEDIMENTATION RATE) 30 H mm/1st hr 0 - 15

RESULT ENTERED BY: SUNIL EHS

Dr. ABHINAY VERMA

Patient Name Mr. DEVI SAHAY MEENA Lab No 4025200 26/02/2024 9:25AM UHID 40010868 **Collection Date** 26/02/2024 9:35AM Age/Gender **Receiving Date** 52 Yrs/Male **Report Date** O-OPD **IP/OP Location** 26/02/2024 6:10PM Dr. EHS CONSULTANT **Referred By Report Status** Final Mobile No. 8290091444

Method:-Modified Westergrens.
Interpretation:-Increased in infections, sepsis, and malignancy.

End Of Report

RESULT ENTERED BY : SUNIL EHS

Page: 10 Of 10

DEPARTMENT OF RADIO DIAGNOSIS

UHID / IP NO	40010868 (5391)	RISNo./Status:	4025200/
Patient Name:	Mr. DEVI SAHAY MEENA	Age/Gender:	52 Y/M
Referred By:	Dr. EHS CONSULTANT	Ward/Bed No:	OPD
Bill Date/No:	26/02/2024 8:52AM/ OPSCR23- 24/14019	Scan Date :	
Report Date :	26/02/2024 10:51AM	Company Name:	Mediwheel - Arcofemi Health Care Ltd.

USG REPORT - ABDOMEN AND PELVIS

LIVER:

Is normal in size and shows diffuse increased echotexture.

No obvious focal lesion seen. No intra hepatic biliary radical dilatation seen.

GALL BLADDER:

Partially distended. Visualized lumen is clear.

PANCREAS:

Is obscured by bowel gases.

SPLEEN:

Appears normal in size and it shows uniform echo texture.

RIGHT KIDNEY:

The shape, size and contour of the right kidney appear normal.

Corticomedullary differentiation is maintained. No evidence of pelvicalyceal dilatation.

No calculi seen.

LEFT KIDNEY:

The shape, size and contour of the left kidney appear normal.

Corticomedullary differentiation is maintained. No evidence of pelvicalyceal dilatation.

No calculi seen.

URINARY BLADDER:

Is normal in contour. No intraluminal echoes are seen. No calculus or diverticulum is seen.

PROSTATE:

Is normal in size, measuring approx. 20-22cc in volume.

No focal fluid collections seen.

IMPRESSION:

Grade-I fatty liver.

DR. RENU JADIYA

Rome Jadiya

Consultant - Radiology

MBBS, DNB

DEPARTMENT OF CARDIOLOGY

UHID / IP NO	40010868 (5391)	RISNo./Status:	4025200/
Patient Name:	Mr. DEVI SAHAY MEENA	Age/Gender:	52 Y/M
Referred By:	Dr. EHS CONSULTANT	Ward/Bed No:	OPD
Bill Date/No:	26/02/2024 8:52AM/ OPSCR23- 24/14019	Scan Date :	
Report Date:	26/02/2024 3:28PM	Company Name:	Final

REFERRAL REASON: HEALTH CHECKUP

2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER

M MODE DIMENSIONS: -

Normal Normal								
IVSD	11.6	6-12mm			LVIDS	25.5	20-40mm	
LVIDD	41.4		32-	57mm		LVPWS	19.3	mm
LVPWD	11.6		6-1	2mm		AO	36.1	19-37mm
IVSS	19.7]	mm		LA	37.6	19-40mm
LVEF	60-62		>	55%		RA	-	mm
	DOPPLER	R MEA	SUREN	1ENTS &	& CALC	ULATIONS	<u>:</u>	
STRUCTURE	MORPHOLOGY	VELOCITY (m/s)		GRADIENT		REGURGITATION		
						(mmHg)		
MITRAL	NORMAL	E	1.08	e'	-	-		NIL
VALVE		A	1.21	E/e'	-			
TRICUSPID	NORMAL	E 0.66		-		NIL		
VALVE			A	0.	68	1		
		A 0.08						
AORTIC	NORMAL	1.43			-		NIL	
VALVE								
PULMONARY	NORMAL	1.30					NIL	
VALVE						-		

COMMENTS & CONCLUSION: -

- ALL CARDIAC CHAMBERS ARE NORMAL
- NO RWMA, LVEF 60-62%
- NORMAL LV SYSTOLIC FUNCTION
- GRADE I LV DIASTOLIC DYSFUNCTION
- ALL CARDIAC VALVES ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

IMPRESSION: - SINUS TACHYCARDIA SEEN DURING STUDY, GRADE I LV DIASTOLIC DYSFUNCTION, NORMAL BI VENTRICULAR SYSTOLIC FUNCTION

DR SUPRIY JAIN
MBBS, M.D., D.M. (CARDIOLOGY)
INCHARGE & SR. CONSULTANT
INTERVENTIONAL CARDIOLOGY

DR ROOPAM SHARMA
MBBS, PGDCC, FIAE
CONSULTANT & INCHARGE
EMERGENCY, PREVENTIVE CARDIOLOGY
AND WELLNESS CENTRE

Patient NameMr. DEVI SAHAY MEENALab No635949

 UHID
 341278
 Collection Date
 26/02/2024 10:56AM

 Age/Gender
 52 Yrs/Male
 Receiving Date
 26/02/2024 10:57AM

 IP/OP Location
 O-OPD
 Report Date
 26/02/2024 12:22PM

Referred By Dr. EHCC Consultant Report Status Final

neport status I ilia



BIOCHEMISTRY

Test Name Result Unit Biological Ref. Range

Sample: Serum

PSA (TOTAL) 0.62 ng/mL 0.00 - 4.00

Total (Free + complexed) PSA - Prostate specific antigen (tPSA)

9773349797

Mobile No.

Method: ElectroChemiLuminescence ImmunoAssay - ECLIA
Interpretation:-PSA determinations are employed are the monitoring of progress and efficiency of therapy in patients with prostate carcinoma or receiving hormonal therapy.

End Of Report

RESULT ENTERED BY: Mr. PANKAJ SHUKLA

Dr. SURENDRA SINGH CONSULTANT & HOD MBBS|MD| PATHOLOGY Dr. ASHISH SHARMA
CONSULTANT & INCHARGE PATHOLOGY
MBBS|MD| PATHOLOGY

Page: 1 Of 1